Tatva Chintan Pharma , a leading specialty chemicals manufacturer, has announced its financial results for the first quarter, showcasing robust growth and improved profitability.

Financial Highlights

The company reported a consolidated revenue from operations of ₹1,168.64 crore for Q1, marking an 11% increase compared to ₹1,054.64 crore in the same quarter last year. This growth was primarily driven by strong performance across its key business segments.

Tatva Chintan's profitability saw a significant improvement, with EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) rising by 37% year-on-year to ₹173.30 crore. The EBITDA margin expanded to 14.8% in Q1, up from 12% in the corresponding quarter of the previous year, reflecting enhanced operational efficiency.

The company's net profit after tax (PAT) grew by 28% to ₹66.50 crore in Q1, compared to ₹52.10 crore in the corresponding quarter of the previous year. Consequently, the earnings per share (EPS) increased to ₹2.84, up from ₹2.23 in the same period last year.

Segment Performance

Tatva Chintan's diverse product portfolio continued to contribute to its growth:

Management Commentary

Chintan N. Shah, Chairman and Managing Director of Tatva Chintan, commented on the results: "We are pleased with our strong start, with double-digit growth in revenue and significant improvement in profitability. Our focus on green chemistry, expanded manufacturing capacity, and increasing global demand for specialty chemicals continues to drive our performance."

Recent Developments

The company also announced several key management changes:

1. Re-appointment of Mr. Chintan Nitinkumar Shah as Managing Director for one year, from February 1, 2026, to January 31, 2027.
2. Re-appointment of Mr. Ajaykumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani as Whole-time Directors for the same period.
3. Re-appointment of three Independent Directors - Mr. Subhash Ambubhai Patel, Mr. Manher Chimanlal Desai, and Mrs. Avani Rajesh Umatt - for a second term of five years, from February 27, 2026, to February 26, 2031.

Additionally, the company announced the resignation of Mr. Ashok Bothra from his position as Chief Financial Officer, effective August 30, 2025.

Outlook

With its strong Q1 performance and strategic focus on sustainable chemistry practices, Tatva Chintan is well-positioned to capitalize on the growing demand for specialty chemicals. The company's continued investments in research and development and manufacturing capabilities are expected to support its long-term growth trajectory in both domestic and international markets.

As Tatva Chintan moves forward, investors and industry observers will be watching closely to see how the company leverages its strengths in green chemistry and expands its global footprint in the specialty chemicals sector.

Tatva Chintan Pharma Chem Limited , a leading specialty chemicals manufacturer, has announced its financial results for the first quarter, along with several key corporate updates.

Financial Highlights

For the quarter ended June 30, Tatva Chintan reported:

• Consolidated revenue from operations of Rs 1,168.64 million, marking a 10.8% increase year-over-year
• Net profit of Rs 66.51 million, up 27.7% compared to the same quarter last year
• EBITDA (excluding other income) of Rs 173.30 million, a significant 37.4% rise year-over-year
• EBITDA margin improved to 14.8% from 12.0% in the corresponding quarter of the previous year

The company's performance shows strong growth in both top-line and bottom-line figures, indicating improved operational efficiency and market demand for its products.

Board Reappointments

The Board of Directors has approved the reappointment of several key executives and independent directors, subject to shareholder approval at the upcoming Annual General Meeting:

• Mr. Chintan Nitinkumar Shah reappointed as Managing Director for one year (February 1, 2026 to January 31, 2027)
• Mr. Ajaykumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani reappointed as Whole-time Directors for one year each (February 1, 2026 to January 31, 2027)
• Mr. Subhash Ambubhai Patel, Mr. Manher Chimanlal Desai, and Mrs. Avani Rajesh Umatt reappointed as Independent Directors for five-year terms (February 27, 2026 to February 26, 2031)

These reappointments reflect the company's confidence in its leadership team and governance structure.

CFO Resignation

In a significant management change, Mr. Ashok Bothra, Chief Financial Officer, has tendered his resignation effective August 30, 2025. Mr. Bothra cited personal and professional goals as reasons for his departure. The company has acknowledged his contributions and commitment to ensuring a smooth transition over the coming weeks.

Segment Performance

Tatva Chintan's results also highlighted the performance of its key product segments:

The diverse product portfolio continues to contribute to the company's overall growth and stability.

Tatva Chintan Pharma Chem Limited's strong performance, coupled with the reaffirmation of its leadership through director reappointments, positions the company well for continued growth in the specialty chemicals sector. However, the upcoming transition in the CFO role will be an important area to watch in the near term.